SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-168975
Filing Date
2023-06-16
Accepted
2023-06-16 16:06:02
Documents
13
Period of Report
2023-06-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d522465d8k.htm   iXBRL 8-K 52536
2 EX-3.1 d522465dex31.htm EX-3.1 113069
  Complete submission text file 0001193125-23-168975.txt   321248

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sage-20230615.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20230615_lab.xml EX-101.LAB 17981
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20230615_pre.xml EX-101.PRE 11257
7 EXTRACTED XBRL INSTANCE DOCUMENT d522465d8k_htm.xml XML 3498
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 231021005
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences